Not available
Quote | ReNeuron Group (OTCMKTS:RNUGF)
Last: | $0.0011 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0011 |
Close: | $0.0011 |
High: | $0.0011 |
Low: | $0.0011 |
Volume: | 2,500 |
Last Trade Date Time: | 04/10/2024 03:00:00 am |
News | ReNeuron Group (OTCMKTS:RNUGF)
2023-05-25 08:25:10 ET ReNeuron Group plc (RNUGF) Q1 2023 Earnings Conference Call May 25, 2023 04:30 AM ET Company Participants Iain Ross - Executive Chairman John Hawkins - CFO Randolph Corteling - Chief Scientific Officer Conference Call Participants ...
(NewsDirect) ReNeuron Group PLC executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors to pr...
Message Board Posts | ReNeuron Group (OTCMKTS:RNUGF)
Subject | By | Source | When |
---|---|---|---|
ReNeuron : Appointments to Scientific Advisory Board | georgejjl | investorshub | 08/23/2019 11:50:20 AM |
Edited Transcript of RENE.L earnings conference call or | georgejjl | investorshub | 07/12/2019 11:44:29 AM |
Well that was an anti-climax. | Spideyboy | investorshub | 07/12/2019 4:43:51 AM |
ReNeuron wins Breakthrough of the Year Award | georgejjl | investorshub | 07/12/2019 2:16:27 AM |
Sold$ RNUGF shares today to buy more $AVXL shares. | georgejjl | investorshub | 07/11/2019 11:55:01 PM |
News, Short Squeeze, Breakout and More Instantly...
ReNeuron Group Company Name:
RNUGF Stock Symbol:
OTCMKTS Market:
(NewsDirect) ReNeuron Group PLC executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors to pr...
LONDON, UK / ACCESSWIRE / October 10, 2022 / ReNeuron Group, a stem cell-derived exosome technology company, has presented encouraging preclinical data highlighting the enhanced drug delivery capability of its customisable exosome platform (CustomEx) over conventional human embryonic kidney-...
LONDON, UK / ACCESSWIRE / October 11, 2021 / ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. T...